240 related articles for article (PubMed ID: 30362181)
1. A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA).
Pang T; Bain SC; Black RNA; Boyle JG; Elliott J; Holcombe A; Lee KCS; Mulligan C; Saunders L; Yousseif A; Baxter M
Diabet Med; 2019 Jan; 36(1):110-119. PubMed ID: 30362181
[TBL] [Abstract][Full Text] [Related]
2. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
[TBL] [Abstract][Full Text] [Related]
3. Experience after switching from insulin glargine U100 to glargine U300 in patients with type 1 diabetes mellitus. A study after one year of treatment in real life.
Pujante Alarcón P; Rodríguez Escobedo R; García Urruzola F; Ares J; Manjón L; Sanchez Ragnarson C; Cacho L; Delgado E; Menéndez Torre EL
Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr; 66(4):210-216. PubMed ID: 30559088
[TBL] [Abstract][Full Text] [Related]
4. Twice- rather than once-daily basal insulin is associated with better glycaemic control in Type 1 diabetes mellitus 12 months after skills-based structured education in insulin self-management.
Hopkinson HE; Jacques RM; Gardner KJ; Amiel SA; Mansell P
Diabet Med; 2015 Aug; 32(8):1071-6. PubMed ID: 25982032
[TBL] [Abstract][Full Text] [Related]
5. A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes.
Tibaldi J; Hadley-Brown M; Liebl A; Haldrup S; Sandberg V; Wolden ML; Rodbard HW
Diabetes Obes Metab; 2019 Apr; 21(4):1001-1009. PubMed ID: 30552800
[TBL] [Abstract][Full Text] [Related]
6. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
7. Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study.
Duque N; Artime E; Romera I; Lebrec J; Díaz S; Rubio M; Sicras-Mainar A; Carretero-Anibarro E; Mundet X; Gorgojo-Martínez JJ; Reviriego J
Adv Ther; 2021 Jul; 38(7):3857-3871. PubMed ID: 34052987
[TBL] [Abstract][Full Text] [Related]
8. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial.
Pasquel FJ; Lansang MC; Khowaja A; Urrutia MA; Cardona S; Albury B; Galindo RJ; Fayfman M; Davis G; Migdal A; Vellanki P; Peng L; Umpierrez GE
Diabetes Care; 2020 Jun; 43(6):1242-1248. PubMed ID: 32273271
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries.
van Mark G; Lanzinger S; Sziegoleit S; Putz FJ; Durmaz M; Borscheller M; Danne T; Seufert J; Holl RW; Bramlage P
Adv Ther; 2019 Jul; 36(7):1628-1641. PubMed ID: 31119688
[TBL] [Abstract][Full Text] [Related]
11. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension.
Riddle MC; Yki-Järvinen H; Bolli GB; Ziemen M; Muehlen-Bartmer I; Cissokho S; Home PD
Diabetes Obes Metab; 2015 Sep; 17(9):835-42. PubMed ID: 25846721
[TBL] [Abstract][Full Text] [Related]
12. Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: Pilot study.
Gradišer M; Berković MC; Bilić-Ćurčić I
Diabetes Res Clin Pract; 2017 Jul; 129():144-147. PubMed ID: 28527305
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the clinical effectiveness and safety of insulin glargine 300 U/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real-world evidence study from Saudi Arabia (EVOLUTION).
Al Malki F; El Damanhoury B; Othman A; Alghamdi Z; AlQahtani M; Madgy A; Chouikrat Z
Diabetes Obes Metab; 2023 Oct; 25(10):2869-2877. PubMed ID: 37485767
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life.
Oriot P; Jérémie W; Buysschaert M
Expert Rev Endocrinol Metab; 2018 May; 13(3):167-171. PubMed ID: 30058899
[TBL] [Abstract][Full Text] [Related]
15. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Home PD; Lam RLH; Carofano WL; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rosenstock J; Hollander PA; Gallwitz B
Diabetes Obes Metab; 2018 Sep; 20(9):2220-2228. PubMed ID: 29766635
[TBL] [Abstract][Full Text] [Related]
17. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
[TBL] [Abstract][Full Text] [Related]
18. Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with Type 1 diabetes.
Elliott J; Jacques RM; Kruger J; Campbell MJ; Amiel SA; Mansell P; Speight J; Brennan A; Heller SR
Diabet Med; 2014 Jul; 31(7):847-53. PubMed ID: 24654672
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
Aroda VR; Rosenstock J; Wysham C; Unger J; Bellido D; González-Gálvez G; Takami A; Guo H; Niemoeller E; Souhami E; Bergenstal RM;
Diabetes Care; 2016 Nov; 39(11):1972-1980. PubMed ID: 27650977
[TBL] [Abstract][Full Text] [Related]
20. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
Riddle MC; Bolli GB; Ziemen M; Muehlen-Bartmer I; Bizet F; Home PD;
Diabetes Care; 2014 Oct; 37(10):2755-62. PubMed ID: 25078900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
